IMV Inc is a clinical-stage immuno-oncology company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.

Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol CT:IMV.

As of 04/14/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  10/09/2009
Outstanding shares:  67,627,541
Average volume:  306,908
Market cap:   $184,623,187
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      40-F
CUSIP:    44974L103
Valuation   (See tab for details)
PE ratio:   -7.31
PB ratio:   4.65
PS ratio:   0.00
Return on equity:   -88.53%
Net income %:   -27,665.87%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy